Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression
International Journal of Molecular Sciences · 11.08.2024 · 25 (16) · 8751
DOI: 10.3390/ijms25168751 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.08.2024. Verfasst von Izabela Sempik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Regional Hospital in Legnica, Iwaszkiewicza 5, 59-220 Legnica, Poland. Hauptthemen laut MEDLINE: Disease Progression, Multiple Sclerosis, Chronic Progressive, Biomarkers. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.
Abstract (Originalsprache)
Primary progressive multiple sclerosis (PPMS), the least frequent type of multiple sclerosis (MS), is characterized by a specific course and clinical symptoms, and it is associated with a poor prognosis. It requires extensive differential diagnosis and often a long-term follow-up before its correct recognition. Despite recent progress in research into and treatment for progressive MS, the diagnosis and management of this type of disease still poses a challenge. Considering the modern concept of progression “smoldering” throughout all the stages of disease, a thorough exploration of PPMS may provide a better insight into mechanisms of progression in MS, with potential clinical implications. The goal of this study was to review the current evidence from investigations of PPMS, including its background, clinical characteristics, potential biomarkers and therapeutic opportunities. Processes underlying CNS damage in PPMS are discussed, including chronic immune-mediated inflammation, neurodegeneration, and remyelination failure. A review of potential clinical, biochemical and radiological biomarkers is presented, which is useful in monitoring and predicting the progression of PPMS. Therapeutic options for PPMS are summarized, with approved therapies, ongoing clinical trials and future directions of investigations. The clinical implications of findings from PPMS research would be associated with reliable assessments of disease outcomes, improvements in individualized therapeutic approaches and, hopefully, novel therapeutic targets, relevant for the management of progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Regional Hospital in Legnica, Iwaszkiewicza 5, 59-220 Legnica, Poland.
- Clinical Department of Neurology, University Centre of Neurology and Neurosurgery, Faculty of Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
- Department of Basic Medical Sciences, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland.
- Department of General and Interventional Radiology and Neuroradiology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
ORCID-Profile: Edyta Dziadkowiak, Helena Moreira
Förderung
- Wroclaw Medical University
Zitieren
APA
Sempik, I., Dziadkowiak, E., Moreira, H., Zimny, A., & Pokryszko-Dragan, A. (2024). Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression. International Journal of Molecular Sciences, 25(16), 8751. https://doi.org/10.3390/ijms25168751
Vancouver
Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A. Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression. International Journal of Molecular Sciences. 2024;25(16):8751. doi:10.3390/ijms25168751
BibTeX
@article{Sempik2024,
author = {Sempik, Izabela and Dziadkowiak, Edyta and Moreira, Helena and Zimny, Anna and Pokryszko-Dragan, Anna},
title = {Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {16},
pages = {8751},
doi = {10.3390/ijms25168751}
}
EUVIMED